Pharmaceutical

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Mar 9, 2024 - 18:00
Johnson & Johnson acquires Ambrx Biopharma for $2bn
Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.
Read the original article

Tags:

Previous Article

SK bioscience to expand vaccine manufacturing plant in South Korea

Next Article

FDA approves BMS’ Opdivo for urothelial carcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

SK bioscience’s typhoid vaccine receives WHO prequalification

SK bioscience’s typhoid vaccine receives WHO prequalifi...

Feb 26, 2024

Senate HELP on collision course

Senate HELP on collision course

Sep 22, 2023

STAT+: Delay of eye drop recall highlights FDA’s impotence on the issue

STAT+: Delay of eye drop recall highlights FDA’s impote...

Nov 21, 2023